KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD


Science & Innovation Theater Webinar 

Recorded on July 12, 2017 

Sponsored by OPKO 


Chronic Kidney Disease (CKD) affects 30 million Americans, with millions more at increased risk. The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on the management of chronic kidney disease–mineral and bone disorder (CKD–MBD) is intended to assist the practitioner caring for adults and children with CKD stages 3–5, on chronic dialysis therapy, or with a kidney transplant. The guideline contains recommendations on evaluation and treatment for abnormalities of CKD–MBD. The newly released 2017 update to these guidelines includes changes that are important for managed care professionals to consider when assessing treatment options for patients with CKD-MBD. Dr. Block, who was a member of the CKD-MBD KDIGO Update Work Group, will highlight potential implications of this update to patients and clinicians. He will also discuss some of the most important updates, including:

  • Diagnosis of CKD-MBD: Biochemical Abnormalities, Bone, and Vascular Calcification
  • Treatment of CKD-MBD Targeted at Lowering High Serum Phosphate and Maintaining Serum Calcium
  • Treatment of Abnormal PTH Levels in CKD-MBD
  • Treatment of Bone with Bisphosphonates, Other Osteoporosis Medications, and Growth Hormone
  • Evaluation and Treatment of Bone Disease


Geoffrey Block, MD
Director of Clinical Research
Colorado Kidney Care 

This webinar is sponsored, developed and presented by the sponsor.  The content of the Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy. 

Sponsored by: